ReviewJournal of molecular medicine (Berlin, Germany)2014
Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications.
Review in Journal of molecular medicine (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Prognostic impact of concomitant leptomeningeal disease in breast cancer patients with brain metastases: a large single-center cohort study.Journal of neuro-oncology · 2026Article
- Novel anti-HER2 nanobody-drug conjugates with enhanced penetration of solid tumor and BBB, reduced systemic exposure and superior antitumor efficacy.Acta pharmacologica Sinica · 2026Article
- Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis.Molecular pharmaceutics · 2023Article
- Comparing the fate of brain metastatic breast cancer cells in different immune compromised mice with cellular magnetic resonance imaging.Clinical & experimental metastasis · 2020Article
- Article
- A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis.Cancer research · 2019Review
- Emerging findings into molecular mechanism of brain metastasis.Cancer medicine · 2018Review
- Article
- Species-dependent extracranial manifestations of a brain seeking breast cancer cell line.PloS one · 2018Article
- Cancer metastasis - tricks of the trade.Bosnian journal of basic medical sciences · 2017Review
- The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.Science translational medicine · 2017Article
- Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.International journal of molecular sciences · 2017Review
- Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.Clinical & experimental metastasis · 2016Article
- Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.Journal of the National Cancer Institute · 2016Article
- Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?Cancer research · 2015Review
- Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.Journal of molecular medicine (Berlin, Germany) · 2015Article
- Invasion and metastasis--recent advances and future challenges.Journal of molecular medicine (Berlin, Germany) · 2015Article
- Emerging strategies for treating brain metastases from breast cancer.Cancer cell · 2015Review
- Mechanisms of disseminated cancer cell dormancy: an awakening field.Nature reviews. Cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer that has metastasized to the brain presents difficult clinical challenges. This diagnosis comes with high mortality rates, largely due to complexities in early detection and ineffective therapies associated with both dormancy and impermeability of the blood-brain barrier (BBB). Magnetic resonance imaging (MRI) is the current gold standard for diagnosis and assessment of brain tumors. It has been used clinically to investigate metastatic development as well as monitor response to therapy. Here, we describe preclinical imaging strategies that we have used to study the development of brain metastases due to breast cancer. Using this approach, we have identified three subsets of metastatic disease: permeable metastases, nonpermeable metastases, and solitary, dormant cancer cells, which likely have very different biology and responses to therapy. The ability to simultaneously monitor the spatial and temporal distribution of dormant cancer cells, metastatic growth, and associated tumor permeability can provide great insight into factors that contribute to malignant proliferation. Our preclinical findings suggest that standard clinical detection strategies may underestimate the true metastatic burden of breast cancer that has metastasized to the brain. A better understanding of true metastatic burden in brains will be important to assist in the development of more effective chemotherapeutics-particularly those targeted to cross the BBB-as well as detection of small nonpermeable metastases.
Indexed as
Identifiers
24306136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.